As you'd imagine, CBD oil is anything other than purified CBD. At very least, in the most purified of oils, it is a mixture of CBD and various anandamide reuptake inhibitors. Several studies indicate that it is a negative allosteric modulator at CB1, and I've therefore avoided it like the plague. A few years ago, I was left to assume (no research!) that it would also be a negative modulator at CB2, so I wasn't interested in the oil for inflammation.... made no sense to me.
However, some recent studies indicate that it's a modest CB2 agonist. So I may give it a try. Unlikely, but maybe. I play it safe, and go full bore agonist.
>> Not sure why anyone would want to invest in the "promise" of anti-obesity companies. Many losers in the past <<
I carry a diabetes susceptibility locus, locked up against the highest normal value for H1B. I'd like a medication that is safe as mother's milk, but I haven't seen other effective molecules available at a MC:book of ~2 and an EV of ~75m. Context is important.
So why would anyone want to invest? Greed. None of those losers had stellar phase II results, upside of 50X, and downside limited largely to burn. Novo, Lilly and others will seriously consider the potential that 1061 preclinical toxicology IS differentiated from belanorab. They'd be dumber than dirt not to do such.
You used the term "invest". Not certain that I "invest" in anything, even long-term holds. I am a serial gambler, and the house often has a pronounced disadvantage. |
